UPDATE

CD ANTIGENS 1993

S. F. Schlossman, L. Boumsell, W. Gilks, J. M. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. L. Silverstein, T. A. Springer, T. F. Tedder, and R. F. Todd

he results of the 5th International Workshop on Human Leukocyte Differentiation Antigens were presented on November 3 through 7, 1993 at a conference held in Boston. Those present at this meeting represent the efforts of more than 500 laboratories worldwide, who have joined together over a two-year period to analyze 1450 antibodies and characterize over 150 molecules. Blind panels for all mAbs, including every CD, every known candidate for CD status, and all mAbs of undefined specificity were analyzed by flow cytometry. Other dedicated laboratories undertook serologic, molecular, biochemical, and histochemical characterization of the mAbs and the structures they defined. The results obtained by all groups showed almost perfect concordance. Detailed results of these studies will be published separately (1). In addition, a Leukocyte Differentiation Antigen Database (LDAD) has been developed to 1) provide identifying information on all molecules and mAbs studied in the workshop; and 2) display and analyze quantitative expression of each molecule on more than 80 cell types¹. Based on these findings, the workshop organizers are pleased to recommend the adoption of 48 new CD clusters and subclusters and the redefinition of 14 previously established clusters. The following table summarizes the additions and changes made to the existing CD nomenclature.

References

 Schlossman, S. F., L. Boumsell, W. Gilks, J. M. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. L. Silverstein, T. A. Springer, T. F. Tedder, and R. F. Todd, eds. 1994. In press. *Leucocyte Typing V: White Cell Differentiation Antigens*. Oxford University Press, Oxford

Table I. CD antigens 1993

| CD Designation | Common Name | Workshop Section | MW Reduced |
|----------------|--|------------------|-------------|
| CD15s | sLe ^x , Sialyl Lewis ^x | ADHESION | |
| CD16 | FcR IIIA/FcR IIIB | MYELOID | 50-65 |
| CD16b | FcR IIIB | MYELOID | 48 |
| CD32 | Previously CDw32, FcRII | MYELOID | 40 |
| CD42a | GPIX | PLATELETS | 23 |
| CD42b | GPIB, α | PLATELETS | 135, 23 |
| CD42c | GP1B-β | PLATELETS | 22 |
| CD42d | GPV | PLATELETS | 85 |
| CD44 | Pgp-1 | ADHESION | 80–90 |
| CD44R | Restricted epitope on CD44 | ADHESION | |
| CD49a | VLA-1, α 1 integrin chain | ADHESION | 210 |
| CD49b | VLA-2, α 2 integrin chain | ADHESION | 160 |
| CD49c | VLA-3, α3 integrin chain | ADHESION | 125 |
| CD49d | VLA-4, α4 integrin chain | ADHESION | 150, 80, 70 |
| CD49e | VLA-5, α 5 integrin chain | ADHESION | 135, 25 |
| CD49f | VLA-6, α 6 integrin chain | ADHESION | 120, 25 |
| CD50 | ICAM-3 | ADHESION | 124 |
| CD51/CD61 | Complex dependent epitope | ADHESION | |
| CD52 | Campath-1 | BLIND | 21–28 |
| CD62E | E-selectin, ELAM-1 | ADHESION | 115 |
| CD62L | L-selectin, LAM-1, TQ-1 | ADHESION | 75–80 |

¹ The LDAD program runs on IBM PCs and via emulation on Macintosh. It may be downloaded freely by anonymous ftp from balrog.nci.nih.gov (156.40.182.2) or purchased on disk (inquire by FAX (301) 480–2052).

Table I. Continued

| CD Designation | Common Name | Workshop Section | MW Reduced |
|----------------|-------------------------------|------------------|----------------------|
| CD62P | P-selectin, GMP-140, PADGEM | ADHESION | 150 |
| CD66a | BGP | MYELOID | 180–200 |
| CD66b | CD67, p100, CGM6 | MYELOID | |
| CD66c | NCA | | 95–100 |
| | | MYELOID | 90–95 |
| CD66d | CGM1 | MYELOID | 30 |
| CD66e | CEA, carcinoembryonic antigen | MYELOID | 180–200 |
| CD67 | Now CD66b | | |
| CD70 | CD27-ligand | ACTIVATION | 55, 75, 95, 110, 170 |
| CDw76 | Previously CD76 | B CELL | NA |
| CD79a | mb-1, Igα | B CELL | 33, 40 |
| CD79b | B29, lgβ | B CELL | 33, 40 |
| CD80 | B7, BB1 | B CELL | 60 |
| CD81 | TAPA-1 | | |
| CD 82 | | B CELL | 22 |
| | R2, IA4, 4F9 | B CELL | 50–53 |
| CD83 | HB15 | B CELL | 43 |
| CDw84 | | B CELL | 73 |
| CD85 | VMP-55, GH1/75 | B CELL | 120, 83 |
| CD86 | FUN-1, BU63 | B CELL | 80 |
| CD87 | UPA-R | MYELOID | 50–65 |
| CD88 | C5aR | MYELOID | |
| CD89 | | | 42 |
| CD09 | FcαR | MYELOID | 55–75 |
| CDw90 | Thy-1 | MYELOID | 25–35 |
| CD91 | α^a M-R | MYELOID | 600 |
| CDw92 | | MYELOID | 70 |
| CD93 | | | |
| | I/D42 | MYELOID | 120 |
| CD94 | KP43 | NK CELL | 43 |
| CD95 | APO-1, FAS | ACTIVATION | 42 |
| CD96 | TACTILE | ACTIVATION | 160 |
| CD97 | | ACTIVATION | 74, 80, 89 |
| CD98 | 4F2, 2F3 | T CELL | 80, 40 |
| CD99 | E2, MIC2 | T CELL | 32 |
| CD99R | CD99 mAb restricted | T CELL | 32 |
| CD100 | BB18, A8 | T CELL | |
| | | | 150 |
| CDw101 | BB27, BA27 | T CELL | 140 |
| CD102 | ICAM-2 | ADHESION | 60 |
| CD103 | HML-1 | adhesion | 150, 25 |
| CD104 | β4 integrin chain | adhesion | 220 |
| CD105 | Endoglin | ENDOTHELIAL | 95 |
| CD106 | VCAM-1, INCAM-110 | ENDOTHELIAL | 100, 110 |
| | | | |
| CD107a | LAMP-1 | PLATELET | 110 |
| CD107b | LAMP-2 | PLATELET | 120 |
| CDw108 | | ADHESION | 80 |
| CDw109 | 8A3, 7D1 | ENDOTHELIAL | 170/150 |
| CD115 | CSF-1R; M-CSFR | MYELOID | 150 |
| CDw116 | HGM-CSFR, GM-CSFR | CYTOKINE | 75-85 |
| CD117 | SCFR, cKIT | CYTOKINE | 145 |
| CDw119 | IFN _y R | CYTOKINE | 90 |
| CD120- | TNED. CELD | CVTOVINE | FF |
| CD120a | TNFR; 55kD | CYTOKINE | 55 |
| CD120b | TNFR; 75KD | CYTOKINE | 75 |
| CDw121a | IL-1R; Type 1 | CYTOKINE | 80 |
| CDw121b | IL-1R; Type 2 | CYTOKINE | 68 |
| CD122 | IL-2R; 75KD, IL-2Rβ | CYTOKINE | 75 |
| CDw124 | IL-4R | CYTOKINE | 140 |
| | | | |
| CD126 | IL-6R | CYTOKINE | 80 |
| CDw127 | IL-7R | CYTOKINE | 75 |
| CDw128 | IL-8R | CYTOKINE | 58–67 |
| CDw130 | IL-6R-gp130SIG | CYTOKINE | 130 |